Overview

Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers

Status:
Unknown status

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

Intercalated administration of Iressa® (gefitinib) on days 5-18 of chemotherapy cycle improve the efficacy of Pemetrexed/platinum regimen given as first-line treatment for never-smokers with advanced (stage IIIB/IV) lung adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Center, Korea

Collaborator:

AstraZeneca

Treatments:

Cisplatin
Gefitinib
Pemetrexed